Related references
Note: Only part of the references are listed.Predictors of survival in patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib
Massimo Iavarone et al.
HEPATOLOGY (2015)
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
et al.
JOURNAL OF HEPATOLOGY (2015)
Hepatocellular Carcinoma: Reasons for Phase III Failure and Novel Perspectives on Trial Design
Josep M. Llovet et al.
CLINICAL CANCER RESEARCH (2014)
Efficacy of sorafenib beyond first progression in patients with metastatic hepatocellular carcinoma
Koji Miyahara et al.
HEPATOLOGY RESEARCH (2014)
Feasibility and efficacy of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma after sorafenib
Takeshi Terashima et al.
HEPATOLOGY RESEARCH (2014)
Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib The EVOLVE-1 Randomized Clinical Trial
Andrew X. Zhu et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
Correlation of progression-free and post-progression survival with overall survival in advanced colorectal cancer
F. Petrelli et al.
ANNALS OF ONCOLOGY (2013)
Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis
T. Pressiani et al.
ANNALS OF ONCOLOGY (2013)
Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials
O. E. Rahma et al.
ANNALS OF ONCOLOGY (2013)
Modified cisplatin/interferon-2b/doxorubicin/5-fluorouracil (PIAF) chemotherapy in patients with no hepatitis or cirrhosis is associated with improved response rate, resectability, and survival of initially unresectable hepatocellular carcinoma
Ahmed O. Kaseb et al.
CANCER (2013)
Postprogression survival for first-line chemotherapy in patients with advanced gastric cancer
Hisato Kawakami et al.
EUROPEAN JOURNAL OF CANCER (2013)
Postprogression Survival of Patients With Advanced Hepatocellular Carcinoma: Rationale for Second-Line Trial Design
Maria Reig et al.
HEPATOLOGY (2013)
Phase II Trial of Palliative Radiotherapy for Hepatocellular Carcinoma and Liver Metastases
Hany Soliman et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
A pilot study of hepatic arterial infusion of chemotherapy for patients with advanced hepatocellular carcinoma who have failed anti-angiogenic therapy
Yu-Yun Shao et al.
LIVER INTERNATIONAL (2013)
Postprogression survival for first-line chemotherapy of patients with advanced non-small-cell lung cancer
H. Hayashi et al.
ANNALS OF ONCOLOGY (2012)
Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma
Julien Edeline et al.
CANCER (2012)
Comparative study between doxorubicin-eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular carcinoma
Myeong Jun Song et al.
JOURNAL OF HEPATOLOGY (2012)
Evaluation of the mRECIST and alpha-Fetoprotein Ratio for Stratification of the Prognosis of Advanced-Hepatocellular-Carcinoma Patients Treated with Sorafenib
Tomokazu Kawaoka et al.
ONCOLOGY (2012)
Diagnosis of Hepatocellular Carcinoma: Newer Radiological Tools
Jeong Min Lee et al.
SEMINARS IN ONCOLOGY (2012)
Targeted Therapies for Hepatocellular Carcinoma
Augusto Villanueva et al.
GASTROENTEROLOGY (2011)
Management of Hepatocellular Carcinoma: An Update
Jordi Bruix et al.
HEPATOLOGY (2011)
Randomized, Phase II Study Comparing Interferon Combined with Hepatic Arterial Infusion of Fluorouracil plus Cisplatin and Fluorouracil Alone in Patients with Advanced Hepatocellular Carcinoma
Tatsuya Yamashita et al.
ONCOLOGY (2011)
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Jacques Ferlay et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
Overall Survival and Post-Progression Survival in Advanced Breast Cancer: A Review of Recent Randomized Clinical Trials
Everardo D. Saad et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Issues and controversies of hepatocellular carcinoma-targeted therapy clinical trials in Asia: experts' opinion
Pei-Jer Chen et al.
LIVER INTERNATIONAL (2010)
Detecting an Overall Survival Benefit that Is Derived From Progression-Free Survival
Kristine R. Broglio et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
Ann-Lii Cheng et al.
LANCET ONCOLOGY (2009)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Progression-free survival is a surrogate for survival in advanced colorectal cancer
Marc Buyse et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Hepatocellular carcinoma with portal vein tumor thrombosis: Clinical characteristics, prognosis, and patient survival analysis
Daichi Takizawa et al.
DIGESTIVE DISEASES AND SCIENCES (2007)
Surrogate end points for median overall survival in metastatic colorectal cancer: Literature-based analysis from 39 Randomized controlled trials of first-line chemotherapy
Patricia A. Tang et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studies
G D'Amico et al.
JOURNAL OF HEPATOLOGY (2006)
Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: Individual patient data from 20,898 patients on 18 randomized trials
DJ Sargent et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Share Paper
